Brief: Provectus Biopharmaceuticals Announces Publication Of Activity Of Pharmaceutical-Grade Rose Bengal Sodium (Rbs) Against Colistin-Resistant Gram-Negative Bacteria
20/04/2023 13:02
April 20 (Reuters) - Provectus Biopharmaceuticals Inc
PVCT.PK :
* PROVECTUS BIOPHARMACEUTICALS ANNOUNCES PUBLICATION OF
ACTIVITY
OF PHARMACEUTICAL-GRADE ROSE BENGAL SODIUM (RBS) AGAINST
COLISTIN-RESISTANT GRAM-NEGATIVE BACTERIA
Source text for Eikon: ID:nGNX33kPZV
Further company coverage: PVCT.PK
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting